A phase 1 study of KD2-396
Latest Information Update: 04 Aug 2023
Price :
$35 *
At a glance
- Drugs KD2-396 (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- 04 Aug 2023 New trial record